Notice2022-18470
Foreign-Trade Zone (FTZ) 35-Philadelphia, Pennsylvania, Notification of Proposed Production Activity, Piramal Pharma Solutions (Pharmaceutical Products), Sellersville, Pennsylvania
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
August 26, 2022
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 165 (Friday, August 26, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 165 (Friday, August 26, 2022)]
[Notices]
[Pages 52505-52506]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-18470]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-37-2022]
Foreign-Trade Zone (FTZ) 35--Philadelphia, Pennsylvania,
Notification of Proposed Production Activity, Piramal Pharma Solutions
(Pharmaceutical Products), Sellersville, Pennsylvania
Piramal Pharma Solutions submitted a notification of proposed
production activity to the FTZ Board (the Board) for its facility in
Sellersville, Pennsylvania under FTZ 35. The notification conforming to
the requirements of the Board's regulations (15 CFR 400.22) was
received on August 19, 2022.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material(s)/component(s) and
specific finished product(s) described in the submitted notification
(summarized below) and subsequently authorized by the Board. The
benefits that may stem from conducting production activity under FTZ
procedures are explained in the background section of the Board's
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>.
The proposed finished products are bempedoic acid and ezetimibe
tablets (180/10 milligrams) (duty-free).
The proposed foreign-status materials are bempedoic acid and
ezetimibe (duty rate ranges from 4% to 6.5%). The request indicates
that the materials are subject to duties under Section 301 of the Trade
Act of 1974 (section 301), depending on the country of origin. The
applicable Section 301 decisions require subject merchandise to be
admitted to FTZs in privileged foreign status (19 CFR 146.41).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive
[[Page 52506]]
Secretary and sent to: <a href="/cdn-cgi/l/email-protection#0b6d7f714b7f796a6f6e256c647d"><span class="__cf_email__" data-cfemail="dcbaa8a69ca8aebdb8b9f2bbb3aa">[email protected]</span></a>. The closing period for their
receipt is October 5, 2022.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Christopher Wedderburn at
<a href="/cdn-cgi/l/email-protection#abe8c3d9c2d885fccecfcfced9c9ded9c5ebdfd9cacfce85ccc4dd"><span class="__cf_email__" data-cfemail="81c2e9f3e8f2afd6e4e5e5e4f3e3f4f3efc1f5f3e0e5e4afe6eef7">[email protected]</span></a>.
Dated: August 23, 2022.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2022-18470 Filed 8-25-22; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on August 26, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.